Flexion Therapeutics Stock News

JPMorgan Chase & Co. increased its position in Flexion Therapeutics Inc (NASDAQ:FLXN) by 18.1% in the first quarter, according to the company in its most recent filing with the Securities & Exchange C

JPMorgan Chase & Co. boosted its stake in Flexion Therapeutics Inc (NASDAQ:FLXN) by 18.1% during the first quarter, according to the company in its most recent filing with the SEC. The institutional i

Flexion Therapeutics (NASDAQ:FLXN) was upgraded by equities researchers at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Friday, BidAskClub reports. A number of other

BURLINGTON, Mass., June 16, 2020 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate.

Later this year the MSO plans a grand production of Mahler's 8th symphony. But will they be able to call on the hundreds of singers they need?

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Teladoc (TDOC – Research Report),

PETALING JAYA: Malaysia is set to have a new operating agreement (OA) for its aviation gateways with the Malaysia Airports Holdings Bhd (MAHB) this year, says Datuk Seri Dr Wee Ka Siong.

In its final season, the coming-of-age drama is as dark, traumatic, and utterly ridiculous as ever.

Q1 2020 Flexion Therapeutics Inc Earnings Call

Miller Value Partners recently released its Q1 2020 Investor Letter, a copy of which you can download below. The Miller Value Partners Opportunity Equity Fund posted a return of -38.4% for the quarter

Flexion (FLXN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Today, we revisit biopharma Flexion Therapeutics. The company has had a tough 2020 so far, as a promising roll out of Zilretta has been sideswiped by the COVID-